Regadenoson
FDA Approved: * April 11, 2022Pharm Company: * APOTEX INC
Category: Heart (Cardiac)
Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.[1] The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects. Regadenoso... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Regadenoson .08 mg/ml Intravenous Injection, Solution
NDC: 0641-6253
Labeler:
Hikma Pharmaceuticals USA Inc.
Regadenoson .08 mg/ml Intravenous Injection, Solution
NDC: 16729-477
Labeler:
Accord Healthcare Inc.
Regadenoson .08 mg/ml Intravenous Injection, Solution
NDC: 36000-364
Labeler:
Baxter Healthcare Corporation
Lexiscan(r) (Regadenoson) .08 mg/ml Intravenous Injection, Solution
NDC: 51662-1448
Labeler:
Hf Acquisition Co LLC, Dba Healthfirst